Immunome
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Immunome sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Immunome: 10 sponsored US clinical trials, 4 recruiting.
Immunome sponsors 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Desmoid, with 1 trials.
Top-decile sponsor footprint
Immunome ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
NCT07505771
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
NCT07610005
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167
A Study of AL102 in Patients With Progressing Desmoid Tumors
NCT04871282
A Varegacestat Hepatic Impairment Study
NCT06841315
A Phase 1 Mass Balance Study of Varegacestat
NCT06845852
A Cardiac Liability Study of Varegacestat in Healthy Participants
NCT06855264
A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants
NCT06677996
IMM-BCP-01 in Mild to Moderate COVID-19
NCT05429021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Immunome pipeline
4 recruiting of 10 indexed (40% open); 4 completed (40%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Desmoid (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Immunome: open-pipeline peers nationwide
Peers matched on 10 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Immunome sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Immunome page
10 registered trials is a research-attention snapshot, not an endorsement of Immunome or any single study.
- 4 of Immunome's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Desmoid is the condition Immunome studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Desmoid trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Immunome pipeline card: 10 registered trials from official public datasets.Report a data error.